Sanjeevani Bio-tech Exim Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Sanjeevani Bio-tech Exim Private Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $2.6M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Sanjeevani Bio-tech Exim Private Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $2.6M Trade | TransData Nexus

Sanjeevani Bio-tech Exim Private Limited

Indian Pharmaceutical Exporter · Antimalarial & Antiparasitic Specialist · $2.6M Total Trade · DGFT Verified

Sanjeevani Bio-tech Exim Private Limited is an Indian pharmaceutical exporter with a total trade value of $2.6M across 2 products in 1 therapeutic categories. Based on 54 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Artemether ($2.5M), Primaquine ($20.5K), .

Sanjeevani Bio-tech Exim Private Limited — Export Portfolio & Destination Treemap

Sanjeevani Bio-tech Exim Private Limited pharmaceutical export portfolio — 2 products across 1 therapeutic categories. Source: Indian Customs (DGFT).

Who is Sanjeevani Bio-tech Exim Private Limited? — Company Overview & Market Position

Sanjeevani Bio-Tech Exim Private Limited (SBEPL) is a privately held pharmaceutical company incorporated on June 9, 2010, in Ahmedabad, Gujarat, India. The company specializes in the export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. As of March 31, 2025, SBEPL reported a total export value of $2.6 million USD across 54 shipments, with a product portfolio concentrated entirely in the Antimalarial & Antiparasitic therapeutic category. The company's registered office is located at D/2004-2009, Sun Central Place, Above Axis Bank, Opposite Iscon Platinum, Ambli, Ahmedabad, Gujarat, 380058, India.

What Does Sanjeevani Bio-tech Exim Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Artemether$2.5M 2Primaquine$20.5K

Sanjeevani Bio-tech Exim Private Limited Therapeutic Categories — 1 Specializations

Product Portfolio — Top 2 by Export Value

Sanjeevani Bio-tech Exim Private Limited exports 2 pharmaceutical products across 1 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Artemether	Antimalarial & Antiparasitic	$2.5M	51	0.3%	11
2	Primaquine	Antimalarial & Antiparasitic	$20.5K	3	1.2%	11

Sanjeevani Bio-tech Exim Private Limited exports 2 pharmaceutical products across 1 therapeutic categories with a total export value of $2.6M. The top category is Antimalarial & Antiparasitic (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Sanjeevani Bio-tech Exim Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

SBEPL operates manufacturing facilities in India, specializing in the production of various pharmaceutical dosage forms, including tablets, capsules, syrups, and injections. The company emphasizes high-quality manufacturing processes to ensure the efficacy and safety of its products. Specific details regarding the locations and capacities of these facilities are not publicly disclosed.

3Key Leadership

The leadership team at SBEPL comprises:

Abhinav Bhargava: Director, appointed on October 14, 2011.

Rajiv Rajendranath Bhargav: Director, appointed on December 21, 2011.

Ranjana Sanjay Bhargav: Director, appointed on October 14, 2011.

These individuals play pivotal roles in steering the company's strategic direction and operations.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Sanjeevani Bio-tech Exim Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

SBEPL's export activities are primarily focused on markets in Asia and South Africa, including countries such as Bangladesh, Yemen, Cambodia, Nigeria, Sudan, the Philippines, Kenya, Somalia, and Dubai. The company has established a global footprint by fulfilling the requirements of clients across these regions. However, specific details regarding regulatory filings, approvals, and market access status in the United States, European Union, United Kingdom, Australia, and Japan are not publicly available.

2Emerging Markets

SBEPL has made significant inroads into emerging markets in Africa, Latin America, and Southeast Asia. The company's products are available in over nine countries, including Nigeria, Kenya, and the Philippines. While the company emphasizes providing affordable quality medicines globally, specific information regarding WHO prequalification or other certifications enabling access to these markets is not publicly disclosed.

3Geographic Strategy

SBEPL's export strategy demonstrates a focused approach, primarily targeting markets in Asia and South Africa. This concentration allows the company to leverage regional expertise and establish strong relationships with clients. However, the lack of diversification into other geographic regions may expose the company to risks associated with market fluctuations and regulatory changes in these specific areas.

Sanjeevani Bio-tech Exim Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific information regarding SBEPL's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history is not publicly available. The company's export activities are primarily focused on markets in Asia and South Africa, and there is no publicly disclosed evidence of FDA approvals or registrations.

2WHO & EU GMP

SBEPL emphasizes high-quality manufacturing processes to ensure the efficacy and safety of its products. However, specific details regarding WHO prequalification, EU Good Manufacturing Practice (GMP) certificates, or European Directorate for the Quality of Medicines & HealthCare (EDQM) status are not publicly disclosed.

3CDSCO & Indian Regulatory

SBEPL operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company holds manufacturing licenses and approvals from state drug controllers, ensuring compliance with Indian pharmaceutical regulations. Specific details regarding export No Objection Certificates (NOCs) are not publicly available.

Sanjeevani Bio-tech Exim Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

SBEPL operates in the competitive pharmaceutical export market, focusing on finished pharmaceutical formulations. While specific competitors in overlapping categories are not publicly disclosed, the company's emphasis on high-quality manufacturing and affordable pricing positions it favorably in the market. However, the lack of diversification in its product portfolio and geographic reach may limit its competitive edge compared to more diversified competitors.

2Key Differentiators

SBEPL's key differentiators include its focus on high-quality manufacturing processes and a product portfolio concentrated entirely in the Antimalarial & Antiparasitic therapeutic category. This specialization allows the company to develop expertise and establish a strong presence in this niche market. However, the concentration of its product portfolio may limit its ability to capitalize on opportunities in other therapeutic areas.

3Strategic Position

SBEPL's current strategic direction appears to be focused on exporting finished pharmaceutical formulations, particularly in the Antimalarial & Antiparasitic category. The company's emphasis on high-quality manufacturing and affordable pricing suggests a commitment to providing accessible healthcare solutions. Future strategic directions may involve diversification of its product portfolio and expansion into new geographic markets to mitigate risks associated with market concentration.

Buyer Due Diligence Brief — Evaluating Sanjeevani Bio-tech Exim Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

SBEPL has established itself as a reliable supplier in the pharmaceutical export market, with a total export value of $2.6 million USD across 54 shipments. The company's focus on high-quality manufacturing processes and affordable pricing indicates a commitment to meeting the needs of its clients. However, the concentration of its product portfolio and geographic reach may impact the consistency and reliability of its supply chain.

2Certifications to Verify

Importers should verify the following certifications when considering SBEPL as a supplier:

FDA Facility Registration: To ensure compliance with U.S. regulatory standards.

WHO Prequalification: To confirm adherence to international quality standards.

EU GMP Certificate: To verify compliance with European manufacturing practices.

Frequently Asked Questions — Sanjeevani Bio-tech Exim Private Limited

How many pharmaceutical products does Sanjeevani Bio-tech Exim Private Limited export from India?

Sanjeevani Bio-tech Exim Private Limited exports 2 pharmaceutical products across 1 therapeutic categories. The top exports are Artemether ($2.5M), Primaquine ($20.5K). Total export value is $2.6M.

What is Sanjeevani Bio-tech Exim Private Limited's total pharmaceutical export value?

Sanjeevani Bio-tech Exim Private Limited's total pharmaceutical export value is $2.6M, based on 54 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Sanjeevani Bio-tech Exim Private Limited cover?

Sanjeevani Bio-tech Exim Private Limited exports across 1 therapeutic categories. The largest are Antimalarial & Antiparasitic (100.0%, 2 products).

Get Full Sanjeevani Bio-tech Exim Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.